Abstract
Background:
In heart failure (HF), obesity, defined as body mass index (BMI) ⩾30 kg m−2, is paradoxically associated with higher survival rates compared with normal-weight patients (the ‘obesity paradox’). We sought to determine if the obesity paradox differed by HF subtype (reduced ejection fraction (HF-REF) versus preserved ejection fraction (HF-PEF)).
Patients and Methods:
A sub-analysis of the MAGGIC meta-analysis of patient-level data from 14 HF studies was performed. Subjects were divided into five BMI groups: <22.5, 22.5–24.9 (referent), 25–29.9, 30–34.9 and ⩾35 kg m−2. Cox proportional hazards models adjusted for age, sex, aetiology (ischaemic or non-ischaemic), hypertension, diabetes and baseline blood pressure, stratified by study, were used to examine the independent association between BMI and 3-year total mortality. Analyses were conducted for the overall group and within HF-REF and HF-PEF groups.
Results:
BMI data were available for 23 967 subjects (mean age, 66.8 years; 32% women; 46% NYHA Class II; 50% Class III) and 5609 (23%) died by 3 years. Obese patients were younger, more likely to receive cardiovascular (CV) drug treatment, and had higher comorbidity burdens. Compared with BMI levels between 22.5 and 24.9 kg m−2, the adjusted relative hazards for 3-year mortality in subjects with HF-REF were: hazard ratios (HR)=1.31 (95% confidence interval=1.15–1.50) for BMI <22.5, 0.85 (0.76–0.96) for BMI 25.0–29.9, 0.64 (0.55–0.74) for BMI 30.0–34.9 and 0.95 (0.78–1.15) for BMI ⩾35. Corresponding adjusted HRs for those with HF-PEF were: 1.12 (95% confidence interval=0.80–1.57) for BMI <22.5, 0.74 (0.56–0.97) for BMI 25.0–29.9, 0.64 (0.46–0.88) for BMI 30.0–34.9 and 0.71 (0.49–1.05) for BMI ⩾35.
Conclusions:
In patients with chronic HF, the obesity paradox was present in both those with reduced and preserved ventricular systolic function. Mortality in both HF subtypes was U-shaped, with a nadir at 30.0–34.9 kg m−2.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Kenchaiah S, Evans J, Levy D, Wilson P, Benjamin EJ, Larson MG et al. Obesity and the risk of heart failure. N Engl J Med 2002; 347: 305–313.
Oreopoulos A, Padwal R, Kalantar-Zadeh K, Fonarow GC, Norris CM, McAlister FA . Body mass index and mortality in heart failure: a meta-analysis. Am Heart J 2008; 156: 13–22.
Lavie CJ, Alpert MA, Arena R, Mehra MR, Milani RV, Ventura HO . Impact of obesity and the obesity paradox on prevalence and prognosis in heart failure. JACC Heart Fail 2013; 1: 93–102.
Ferreira I, Stehouwer CDA . Obesity paradox or inappropriate study designs? Time for life-course epidemiology. J Hypertens 2012; 30: 2271–2275.
Banack HR, Kaufman JS . The ‘Obesity Paradox’ Explained. Epidemiology 2013; 24: 461–462.
Greenberg JA . The obesity paradox in the US population. Am J Clin Nutr 2013; 97: 1195–1200.
Lavie CJ, Mehra MR, Milani RV . Obesity and heart failure prognosis: paradox or reverse epidemiology? Eur Heart J 2005; 26: 5–7.
Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J 2012; 33: 1750–1757.
Gustafsson F, Kragelund CB, Torp-Pedersen C, Seibaek M, Burchardt H, Akkan D et al. Effect of obesity and being overweight on long-term mortality in congestive heart failure: influence of left ventricular systolic function. Eur Heart J 2005; 26: 58–64.
Pocock SJ, Ariti CA, McMurray JJV, Maggioni A, Kober L, Squire IB et al. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. Eur Heart J 2013; 34: 1404–1413.
Kalantar-Zadeh K, Horwich TB, Oreopoulos A, Kovesdy CP, Younessi H, Anker SD et al. Risk factor paradox in wasting diseases. Curr Opin Clin Nutr Metab Care 2007; 10: 433–442.
Lavie CJ, Milani RV, Artham S, Patel D, Ventura HO . The obesity paradox, weight loss, and coronary disease. Am J Med 2009; 122: 1106–1114.
Flegal KM, Graubard BI, Williamson DF, Cooper RS . Reverse causation and illness-related weight loss in observational studies of body weight and mortality. Am J Epidemiol 2010; 173: 1–9.
Oreopoulos A, Ezekowitz JA, McAlister FA, Kalantar-Zadeh K, Fonarow GC, Norris CM et al. Association between direct measures of body composition and prognostic factors in chronic heart failure. Mayo Clin Proc 2010; 85: 609–617.
Oreopoulos A, Fonarow GC, Ezekowitz JA, McAlister FA, Sharma AM, Kalantar-Zadeh K et al. Do anthropometric indices accurately reflect directly measured body composition in men and women with chronic heart failure? Congest Heart Fail 2011; 17: 90–92.
Oreopoulos A, Kalantar-Zadeh K, Sharma A, Fonarow G . The obesity paradox in the elderly: potential mechanisms and clinical implications. Clin Geriatr Med 2009; 25: 643–659.
Lavie CJ, De Schutter A, Patel DA, Milani RV . Body composition and fitness in the obesity paradox—Body mass index alone does not tell the whole story. Prev Med 2013; 57: 1–2.
Lavie CJ, Cahalin LP, Chase P, Myer J, Bensimhon D, Peberdy MA et al. Impact of cardiorespiratory fitness on the obesity paradox in patients with heart failure. Mayo Clin Proc 2013; 88: 251–258.
McAuley PA, Artero EG, Sui X, Lee D, Church TS, Lavie CJ et al. The obesity paradox, cardiorespiratory fitness, and coronary heart disease. Mayo Clin Proc 2012; 87: 443–451.
Clark AL, Chyu J, Howrwich TB . The obesity paradox in men versus women with systolic heart failure. Am J Cardiol 2012; 110: 77–78.
Lavie CJ, Osman AF, Milani RV, Mehra MR . Body composition and prognosis in chronic systolic heart failure: the obesity paradox. Am J Cardiol 2003; 91: 891–894.
Coutinho T, Goel K, Corrêa de Sá D, Carter RE, Hodge DO, Kragelund C et al. Combining body mass index with measures of central obesity in the assessment of mortality in subjects with coronary disease. J Am Coll Cardiol 2013; 61: 553–560.
Pocock SJ, McMurray JJV, Dobson J, Yusuf S, Granger CB, Michelson EL et al. Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. Eur Heart J 2008; 29: 2641–2650.
Acknowledgements
FAM is supported by salary awards from Alberta Innovates-Health Solutions and the Capital Health Chair in Cardiovascular Outcomes Research; KKP is supported by a Research Fellowship from the New Zealand Heart Foundation; RND holds the New Zealand Heart Foundation Chair in Heart Health; and MRC is supported by the National Institute for Health Research Cardiovascular Biomedical Research Unit at the Royal Brompton Hospital, London, UK. RP and FAM are supported by an alternate funding plan from the Government of Alberta. The MAGGIC meta-analysis was supported by grants from the New Zealand National Heart Foundation, the University of Auckland and the University of Glasgow.
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Disclaimer
These sponsors had no role in the design, conduct, data management and analysis, manuscript preparation or review, nor in the authorization for submission.
Appendices
MAGGIC Executive Group:
C Berry, R Doughty, C Granger, L Køber, B Massie, F McAlister, J McMurray, S Pocock, K Poppe, K Swedberg, J Somaratne, G Whalley.
MAGGIC Steering Group:
A Ahmed, B Andersson, A Bayes-Genis, C Berry, M Cowie, R Cubbon, R Doughty, J Ezekowitz, J Gonzalez-Juanatey, M Gorini, I Gotsman, L Grigorian-Shamagian, M Guazzi, M Kearney, L Køber, M Komajda, A di Lenarda, M Lenzen, D Lucci, S Macín, B Madsen, A Maggioni, M Martínez-Sellés, F McAlister, F Oliva, K Poppe, M Rich, M Richards, M Senni, I Squire, G Taffet, L Tarantini, C Tribouilloy, R Troughton, H Tsutsui, G Whalley.
MAGGIC Coordinating Centre:
R Doughty, N Earle, GD Gamble, K Poppe, G Whalley, the University of Auckland, New Zealand.
MAGGIC Statistical Group:
C Ariti, J Dobson, GD Gamble, S Pocock, K Poppe.
Studies included:
AHFMS: RN Doughty, G Whalley; Andersson (2 data sets): B Andersson, C Hall; BATTLESCARRED and Richards: AM Richards, R Troughton, J Lainchbury; Berry: C Berry, K Hogg, J Norrie, K Stevenson, M Brett, J McMurray; CHARM: MA Pfeffer, K Swedberg, CB Granger, P Held, JJV McMurray, EL Michelson, B Olofsson, J Östergren, S Yusuf for the CHARM Investigators and Committees; Diamond and ECHOS: L Køber, C Torp-Pedersen; DIG Trial: DIG limited access data, Ali Ahmed; Euro HF Survey: MJ Lenzen, WJM Scholte op Reimer, E Boersma, PJMJ Vantrimpont, F Follath, K Swedberg, J Cleland, M Komajda; Gotsman: I Gotsman, D Zwas, D Planer, T Azaz-Livshits, D Admon, C Lotan, A Keren; Grigorian-Shamagian: L Grigorian-Shamagian, A Varela-Roman, P Mazón-Ramos, P Rigeiro-Veloso, MA Bandin-Dieguez, JR Gonzalez-Juanatey; Guazzi: M Guazzi, J Myers, R Arena; Heart Failure Clinic Edmonton: FA McAlister, J Ezekowitz, PW Armstrong, Bibiana Cujec, Ian Paterson; Hillingdon: MR Cowie, DA Wood, AJS Coats, SG Thompson, V Suresh, PA Poole-Wilson, GC Sutton; HOLA: M Martínez-Sellés, JAG Robles, L Prieto, MD Muñoa, E Frades, O Díaz-Castro, J Almendral; Italian HF Registry (IN-CHF): L Tarantini, P Faggiano, M Senni, D Lucci, D Bertoli, M Porcu, C Opasich, L Tavazzi, AP Maggioni; Kirk: V Kirk, M Bay, J Parner, K Krogsgaard, TM Herzog, S Boesgaard, C Hassager, OW Nielsen, J Aldershvile, H Nielsen L Kober; Macin: SM Macín, ER Perna, JP Cimbaro Canella, P Alvarenga, R Pantich, N Ríos, EF Farias, JR Badaracco; Madsen: BK Madsen, JF Hansen, KH Stokholm, J Brons, D Husum, LS Mortensen; MUSIC: A Bayes-Genis, R Vazquez, T Puig, C Fernandez-Palomeque, A Bardají, D Pascual-Figal, J Ordoñez-Llanos, M Valdes, A Gabarrus, R Pavon, L Pastor, JR Gonzalez-Juanatey, J Almendral, M Fiol,V Nieto, C Macaya, J Cinca, A Bayes de Luna; Newton: JD Newton, HM Blackledge, IB Squire; NPC I: SP Wright, GA Whalley, RN Doughty; Rich (data set 1): R Kerzner, BF Gage, KE Freedland, MW Rich: Rich (data set 2): BC Huynh, A Rovner, KE Freedland, RM Carney, MW Rich; Taffet: GE Taffet, TA Teasdale, AJ Bleyer, NJ Kutka, RJ Luchi; Tribouilloy: C Tribouilloy, D Rusinaru, H Mahjoub, V Soulière, F Lévy, M Peltier; Tsutsui: H Tsutsui, M Tsuchihashi, A Takeshita; UK Heart Study: PA MacCarthy, MT Kearney, J Nolan, AJ Lee, RJ Prescott, AM Shah, WP Brooksby, KAA Fox; Varela-Roman: A Varela-Roman, JR Gonzalez-Juanatey, P Basante, R Trillo, J Garcia-Seara, JL Martinez-Sande, F Gude.
Rights and permissions
About this article
Cite this article
Padwal, R., McAlister, F., McMurray, J. et al. The obesity paradox in heart failure patients with preserved versus reduced ejection fraction: a meta-analysis of individual patient data. Int J Obes 38, 1110–1114 (2014). https://doi.org/10.1038/ijo.2013.203
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ijo.2013.203
Keywords
This article is cited by
-
Circulating level of β-aminoisobutyric acid (BAIBA), a novel myokine-like molecule, is inversely associated with fat mass in patients with heart failure
Heart and Vessels (2024)
-
New-onset atrial fibrillation in patients with worsening heart failure and coronary artery disease: an analysis from the COMMANDER-HF trial
Clinical Research in Cardiology (2022)
-
Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS
Journal of Neuro-Oncology (2022)
-
Obesity, inflammation, and heart failure: links and misconceptions
Heart Failure Reviews (2022)
-
High percent body fat mass predicts lower risk of cardiac events in patients with heart failure: an explanation of the obesity paradox
BMC Geriatrics (2021)